Arthritis Tag

AI-Supported Digital Care Improves Rheumatoid Arthritis Outcomes After Hospital Discharge

Key Takeaways: 

• A nurse-led, AI-assisted digital platform reduced disease activity and improved physical function more than routine care over six months.
  
• People using the platform showed higher medication adherence and markedly greater satisfaction with their care.
  
• Real-time monitoring enabled earlier detection of problems and more personalised support between clinic visits.
  
  
  

The challenge of care after discharge

Rheumatoid arthritis is a long-term autoimmune condition that causes joint pain, swelling and a progressive loss of function. Managing it well once people leave hospital is often difficult, because symptoms can fluctuate and regular follow-up is not always easy to arrange. A recent real-world study set out to test whether an artificial intelligence (AI)-assisted digital care platform could improve outcomes for people living with the condition after discharge.

How the study was designed

The study, published in JMIR Medical Informatics and conducted by Ziyun Zhang, PhD, and colleagues at Tongji Hospital, followed 341 people with rheumatoid arthritis over a six-month period in a real clinical setting.

Participants were divided into two groups. One group received standard post-discharge care, while the other used a nurse-led digital management platform supported by AI. The platform allowed people to report symptoms, fatigue, medication use, laboratory results and emotional wellbeing through a smartphone app. This information was stored securely and analysed in real time. When the system detected concerning changes, healthcare staff were alerted so that they could respond quickly. Nurses and health coaches also provided ongoing education and personalised support.

The researchers focused on how disease activity, physical function, medication adherence and satisfaction changed over time, using standard clinical tools to measure disease severity and disability.

What the platform achieved

After six months, both groups showed some improvement, but the differences between them were notable. People using the AI-supported platform experienced a greater reduction in disease activity scores, meaning their arthritis was better controlled. They also showed significant improvements in physical function compared with those receiving routine care alone.

Medication adherence was higher in the digital care group, with more people taking their medicines as prescribed. Satisfaction levels were significantly higher too, with a large majority of those using the platform reporting that they were very satisfied with their care experience, compared with the standard care group.

What it means for long-term management

The authors conclude that the combination of AI monitoring, nurse-led support and continuous digital engagement helped to improve both clinical outcomes and the experience of care. The system made it easier to detect problems early, encourage medication use and provide more personalised care between clinic visits.

Overall, the study suggests that digital health platforms could play an important role in improving the long-term management of rheumatoid arthritis, particularly by keeping people more closely connected to their care teams after they leave hospital.

GLP-1 Receptor Agonists May Reduce Rheumatoid Arthritis Activity and Cardiovascular Risk in People with Obesity

Key Takeaways:

• GLP-1 receptor agonists were linked to reduced rheumatoid arthritis (RA) disease activity and improved cardiovascular risk factors in people with obesity or overweight.
  
• Significant improvements were observed in inflammation markers, weight, and cholesterol levels over 12 months of treatment.
  
• Findings suggest GLP-1RAs could offer dual benefits by addressing both metabolic and inflammatory disease processes in RA.
  
  
  

GLP-1RAs show promise in managing RA and cardiometabolic health

The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with improvements in both rheumatoid arthritis (RA) disease activity and cardiovascular risk factors among people living with overweight or obesity, according to new research published in ACR Open Rheumatology.

Rheumatoid arthritis frequently coexists with obesity, which is known to exacerbate systemic inflammation, increase disease activity, and reduce response to treatment. Although GLP-1RAs are well established for treating obesity, type 2 diabetes, and for reducing cardiovascular risk, their potential role in inflammatory diseases such as RA has not been clearly defined.

Study overview

Researchers at the University of California, Los Angeles (UCLA) conducted a single-centre, retrospective observational study involving people with RA and a body mass index (BMI) of at least 27 kg/m². Participants were prescribed either semaglutide (oral or subcutaneous) or tirzepatide (subcutaneous) between 2018 and 2024.

Out of 554 screened individuals, 229 met the inclusion criteria. Of these, 173 took the prescribed GLP-1RA and formed the treatment cohort, while 42 individuals served as controls, having been prescribed but not initiating therapy. Participants were evaluated at 3-month intervals for up to 12 months.

Baseline characteristics

Both groups were broadly similar in terms of BMI, RA duration, and the use of conventional, biologic, or targeted synthetic disease-modifying antirheumatic drugs (DMARDs). However, diabetes (49% vs 14%) and hypertension (57% vs 38%) were more common in the treatment group.

The mean baseline BMI was 37.1 kg/m² among those receiving treatment and 35.3 kg/m² among control individuals. A greater proportion of participants in the treatment group were White (71% vs 47%).

Improvements in RA and cardiometabolic outcomes

People who took GLP-1RAs showed significantly greater improvements in several clinical measures compared with those who did not initiate therapy:

• RA disease activity scores: decreased by −0.03 versus an increase of +0.21 in controls (P = .03)
  
• Visual analogue scale (VAS) pain scores: decreased by −0.6 cm versus an increase of +1.3 cm in controls (P < .001)
  
• Weight: reduced by −6.2 kg versus −1.7 kg (P < .001)
  
• Total cholesterol: decreased by −10.3 mg/dL versus +0.3 mg/dL (P = .04)
  
• HbA1c: reduced by −0.4% versus +0.1% (P = .03)
  

Within the treatment group, significant reductions were also noted in inflammatory and lipid parameters, including:

• Erythrocyte sedimentation rate (ESR): −5.4 mm/hr (P = .004)
  
• C-reactive protein (CRP): −0.9 mg/dL (P = .004)
  
• Low-density lipoprotein (LDL) cholesterol: −7.3 mg/dL (P = .002)
  
• Triglycerides: −10.5 mg/dL (P = .004)
  
  
  

Tolerability and limitations

Adverse effects were relatively common, with 29% of participants discontinuing treatment, most frequently due to gastrointestinal symptoms or insurance-related issues.

Sensitivity analyses that accounted for comorbidities and serostatus did not significantly alter the study’s outcomes. However, researchers noted several limitations, including the single-centre, retrospective design, reliance on chart abstraction rather than validated disease activity indices, and the possibility of residual confounding.

Clinical implications

“Going forward, clinicians may consider integrating GLP-1RAs into the treatment regimens for patients with [RA and obesity], not only to target obesity-related complications but also possibly to target the underlying inflammatory disease process,” the authors concluded.

Some study authors disclosed affiliations with biotechnology, pharmaceutical, and medical device companies. A full list of disclosures is available in the original publication.